Epitinib is a Small Molecule owned by Hutchison MediPharma, and is involved in 2 clinical trials, which were completed.
HMPL-813 is an anti-cancer agent. The drug candidate acts by blocking the epidermal growth factor receptor(EGFR). Epidermal growth factor (EGF) attaches to its receptor EGFR and results in receptor activation. Activation of the EGFR further causes autophosphorylation of key tyrosine residues. These pathways act in a coordinated manner to promote cell differentiation. The drug candidate selectively blocks EGFR and inhibits uncontrolled proliferation of the cell.
The revenue for Epitinib is expected to reach a total of $2.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Epitinib NPV Report.
HMPL-813 (Epitinib) is under development for the treatment of glioblastoma multiforme. It is an orally active small molecule. It acts by targeting EGFR signalling pathway and induced cell cycle arrest and apoptosis. The drug candidate was also under development for the treatment of esophageal cancer, solid tumors metastasized to the brain and non-small cell lung cancer.
Hutchmed China Overview
Hutchmed China (Hutchmed) formerly known as Hutchison China MediTech is a biopharmaceutical company which discovers, develops, manufactures and commercializes drugs for the treatment of solid tumors and hematological malignancies; and immunological disorders. It also offers over-the-counter (OTC) pharmaceuticals and consumer healthcare products. Hutchmed also provides R&D services to other companies. It has a broad pipeline of drug candidates indicated for the treatment of immunological diseases, besides novel oral drug candidates for various cancers and inflammation. It operates in China, North America, Europe and Australia. The company offers prescription drugs to hospitals in China through direct sales force. It distributes consumer health products in China. Hutchmed is headquartered in Kowloon, Hong Kong.
The company reported revenues of (US Dollars) US$356.1 million for the fiscal year ended December 2021 (FY2021), an increase of 56.2% over FY2020. The operating loss of the company was US$207 million in FY2021, compared to an operating loss of US$196.7 million in FY2020. The net loss of the company was US$194.7 million in FY2021, compared to a net loss of US$125.7 million in FY2020.
Quick View – Epitinib
|Highest Development Stage|